Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Obesity drug market heats up in India; Novo Nordisk advances Wegovy launch from 2026 to coming months to challenge Eli ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

--Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources.

Novo Nordisk will invest $1.09 billion in Brazil to enhance production of injectable drugs for obesity and diabetes. This ...

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden ...